Catalyst Pharmaceuticals saw the highest growth of 0.99% in patent filings and no patents were granted in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Catalyst Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Catalyst Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 100% of filings. The European Patent Office(EPO) patent Office are among the top ten patent offices where Catalyst Pharmaceuticals is filings its patents..
Bayer and Amgen could be the strongest competitors for Catalyst Pharmaceuticals
Patents related to climate change lead Catalyst Pharmaceuticals's portfolio
Catalyst Pharmaceuticals has the highest number of patents in climate change. For climate change, nearly 100% of patents were filed and no patents were granted in Q2 2024.
For comprehensive analysis of Catalyst Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.